申请人:Takeda Pharmaceutical Company Limited
公开号:EP1604983A1
公开(公告)日:2005-12-14
A compound represented by the formula (I):
wherein ring A represents an aromatic ring; X represents a bond, oxygen, NR4 (R4 represents hydrogen, a hydrocarbon group, or a heterocyclic group), or alkylene; R1 represents a hydrocarbon group, or a heterocyclic group; R2 represents -COYR5 (Y represents a bond, alkylene, oxygen, sulfur, or NR6 (R6 represents hydrogen, a hydrocarbon group, or a heterocyclic group), and R5 represents a hydrocarbon group, or a heterocyclic group), a hydrocarbon group, or a heterocyclic group; and R3 represents a hydrocarbon group, a heterocyclic group, optionally substituted hydroxy, optionally substituted amino, or -S(O)nR7 (R7 represents a hydrocarbon group, or a heterocyclic group, and n is 0 to 2), a salt of the compound, or a prodrug or either is useful as an agent for modulating the function of an RFRP receptor.
由式(I)代表的化合物:
其中环 A 代表芳香环;X 代表键、氧、NR4(R4 代表氢、烃基或杂环基)或亚烷基;R1 代表烃基或杂环基;R2 代表-COYR5(Y 代表键、亚烷基、氧、硫或 NR6(R6 代表氢、烃基或杂环基和 R3 代表烃基、杂环基、任选取代的羟基、任选取代的氨基或-S(O)nR7(R7 代表烃基或杂环基,且 n 为 0 至 2),该化合物的盐、原药或二者之一可用作调节 RFRP 受体功能的制剂。